These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 10967445)

  • 21. Galenical development of a new sustained-release theophylline pellet formulation for once-daily administration.
    Benedikt G; Steinijans VW; Dietrich R
    Arzneimittelforschung; 1988 Aug; 38(8A):1203-9. PubMed ID: 3190808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Properties of drug-containing spherical pellets produced by a hot-melt extrusion and spheronization process.
    Young CR; Koleng JJ; McGinity JW
    J Microencapsul; 2003; 20(5):613-25. PubMed ID: 12909545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Absorption profile and absolute bioavailability of a theophylline sustained-release preparation].
    Pabst G; Weber W; Barkworth MF; Müller M; Rehm KD
    Arzneimittelforschung; 1998 May; 48(5A):574-9. PubMed ID: 9676347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioavailability and pharmacokinetics of a new controlled-release theophylline preparation in the form of capsules containing pellets.
    Valenti S; Crimi P; Brusasco V
    Respiration; 1987; 52(3):195-200. PubMed ID: 3438582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of drying on microstructure and drug release profiles from tablets of MCC-lactose-Carbopol and MCC-dicalcium phosphate-Carbopol pellets.
    Gómez-Carracedo A; Souto C; Marti Nez-Pacheco R; Concheiro A; Gómez-Amoza JL
    Eur J Pharm Biopharm; 2008 Jun; 69(2):675-85. PubMed ID: 18248805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic profile of a new sustained-release theophylline pellet formulation for once-daily evening administration.
    Steinijans VW; Sauter R; Böhm A; Staudinger H
    Arzneimittelforschung; 1988 Aug; 38(8A):1241-50. PubMed ID: 3190813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sintering of wax for controlling release from pellets.
    Singh R; Poddar SS; Chivate A
    AAPS PharmSciTech; 2007 Sep; 8(3):E74. PubMed ID: 17915824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug release from MCC- and carrageenan-based pellets: experiment and theory.
    Kranz H; Jürgens K; Pinier M; Siepmann J
    Eur J Pharm Biopharm; 2009 Oct; 73(2):302-9. PubMed ID: 19465119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained release pellets based on poly(N-isopropyl acrylamide): matrix and in situ photopolymerization-coated systems.
    Mayo-Pedrosa M; Alvarez-Lorenzo C; Lacík I; Martinez-Pacheco R; Concheiro A
    J Pharm Sci; 2007 Jan; 96(1):93-105. PubMed ID: 16967440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel floating controlled release drug delivery system prepared by hot-melt extrusion.
    Vo AQ; Feng X; Morott JT; Pimparade MB; Tiwari RV; Zhang F; Repka MA
    Eur J Pharm Biopharm; 2016 Jan; 98():108-21. PubMed ID: 26643801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quality improvement of melt extruded laminar systems using mixture design.
    Hasa D; Perissutti B; Campisi B; Grassi M; Grabnar I; Golob S; Mian M; Voinovich D
    Eur J Pharm Sci; 2015 Jul; 75():169-76. PubMed ID: 25912827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Physical and thermal characterisation of Precirol and Compritol as lipophilic glycerides used for the preparation of controlled-release matrix pellets.
    Hamdani J; Moës AJ; Amighi K
    Int J Pharm; 2003 Jul; 260(1):47-57. PubMed ID: 12818809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Melt extruded helical waxy matrices as a new sustained drug delivery system.
    Hasa D; Perissutti B; Grassi M; Zacchigna M; Pagotto M; Lenaz D; Kleinebudde P; Voinovich D
    Eur J Pharm Biopharm; 2011 Nov; 79(3):592-600. PubMed ID: 21827851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Theoretical and experimental study on theophylline release from stearic acid cylindrical delivery systems.
    Grassi M; Voinovich D; Franceschinis E; Perissutti B; Filipovic-Grcic J
    J Control Release; 2003 Oct; 92(3):275-89. PubMed ID: 14568409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of kappa-carrageenan as alternative pelletisation aid to microcrystalline cellulose in extrusion/spheronisation. II. Influence of drug and filler type.
    Thommes M; Kleinebudde P
    Eur J Pharm Biopharm; 2006 May; 63(1):68-75. PubMed ID: 16325384
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melt pelletisation of a hygroscopic drug in a high shear mixer. Part 2. Mutual compensation of influence variables.
    Thies R; Kleinebudde P
    Eur J Pharm Sci; 2000 Apr; 10(2):103-10. PubMed ID: 10727875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feasibility of in-vitro/in-vivo correlation in the case of a new sustained-release theophylline pellet formulation.
    Dietrich R; Brausse R; Benedikt G; Steinijans VW
    Arzneimittelforschung; 1988 Aug; 38(8A):1229-37. PubMed ID: 3190811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and study of ibuprofen disintegrating sustained-release tablets comprising coated pellets.
    Abbaspour MR; Sadeghi F; Afrasiabi Garekani H
    Eur J Pharm Biopharm; 2008 Mar; 68(3):747-59. PubMed ID: 17977701
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of plasticizer type and level on the properties of Eudragit S100 matrix pellets prepared by hot-melt extrusion.
    Schilling SU; Lirola HL; Shah NH; Waseem Malick A; McGinity JW
    J Microencapsul; 2010; 27(6):521-32. PubMed ID: 20575612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Controlled drug release from Gelucire-based matrix pellets: experiment and theory.
    Siepmann F; Muschert S; Flament MP; Leterme P; Gayot A; Siepmann J
    Int J Pharm; 2006 Jul; 317(2):136-43. PubMed ID: 16621362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.